A £2.48 million gift from founding and principal donor XTX Markets, the global algorithmic trading ...
Illumina hails Egypt’s aspirations for utilizing genomics in healthcare issues
Paula Dowdy – SVP and General Manager of EMEA region at llumina – has lauded Egyptian government’s aspirations for utilizing genomics to help tackle national healthcare issues, like cancer and genetic disease, given the national Egyptian Genome Project.
Dowdy made the remarks after her meeting with Egyptian Prime Minister Moustafa Madbouli at a US Chamber of Commerce virtual roundtable celebrating one century of bilateral US-Egypt ties.
In the same context, Illumina expressed its gratitude for participating in the inaugural edition of the First African Medical Conference, which was organized by the Egyptian Authority for Standardized Procurement and Medical Supply and Medical Technology Management, under the auspices of President Abdel Fattah El Sisi.
The event brought together experts and leaders in the field of medicine.
Samia Cherif, Illumina’s Head of Government Affairs for the Middle East, expressed her gratitude to be part of this event.
“During our participation in Africa Health Excon, we held several meetings with key officials and decision-makers in the government regarding the support we at Illumina can offer with regards to genome research, while focusing on rare diseases, blood diseases and the presidential initiative for the early detection of genetic diseases as well,” she said.
Cherif added, “We are very proud to participate in this event, as it highlights one of the biggest issues we are tackling today, which is the support and management of the health sector. This conference is not only a testimony of the unlocked potential of healthcare reform in our society, but to the strides we can make through unified and strategic partnerships.”
Using state-of-the-art technology, Illumina has positioned itself as a global leader in understanding human health through genomics.
The core of Illumina’s vision is to use innovative technologies to better analyze genetic variation and function, and to empower the economy by exploring DNA at a larger scale than ever before. Through their services, doctors and patients can answer questions regarding cell mutation, disease origins or preventing future outbreaks.